CSL (OTCMKTS:CSLLY) Raised to Hold at Zacks Research

CSL (OTCMKTS:CSLLY) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Separately, Canaccord Genuity Group upgraded CSL to a “hold” rating in a research report on Monday, October 6th. One research analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy”.

CSL Stock Down 0.2%

Shares of CSL stock opened at $71.23 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.12 and a current ratio of 2.46. CSL has a 1 year low of $61.06 and a 1 year high of $100.75. The business has a 50 day moving average price of $69.95 and a 200 day moving average price of $76.54.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.